ImmuPharma plc (LON:IMM – Get Free Report) reached a new 52-week low during mid-day trading on Thursday. The company traded as low as GBX 3.01 and last traded at GBX 3, with a volume of 2,133,755 shares. The stock had previously closed at GBX 3.25.
ImmuPharma Stock Performance
The firm has a market cap of £18.79 million, a P/E ratio of -3.62 and a beta of 3.02. The firm’s fifty day moving average is GBX 3.63 and its 200 day moving average is GBX 4.69.
ImmuPharma (LON:IMM – Get Free Report) last released its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.84) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 559.87%. As a group, equities research analysts forecast that ImmuPharma plc will post -339.00 EPS for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
